If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies could one day lead the sector thanks to their innovative pipeline programs and attractiveness to collaborators.

However, both stocks have had a rough go of it lately, falling sharply over the past 12 months even as the overall stock market has gained. So which has a better chance of going on to recover and reward its investors now?

Recursion is near the start of its growth story. In case you're not familiar, its business has three segments, but only two have any chance of yielding revenue in the near term.

Continue reading

Source Fool.com